focus -WSS

focus

author：knowledge 2025-09-28 21:58:12 - browse：8

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Future doctors should be trained to promote social change

hotspot

WSS

ER docs worry over extreme heat as a 'mass casualty event'

A strong 6.5

US soldier in North Korean custody after crossing DMZ line

Positive childhood experiences can help future health

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Study: Hearing aids may slow cognitive decline in those at risk

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Alkermes shareholders re

Readout Newsletter: Bluebird, CVS, Contineum

Medicare proposal to cover medical devices draws a mixed reaction

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Virginia high school admissions case could be legal follow

Asbestos, a deadly carcinogen, banned by EPA

Medical records are filled with copy

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

Affirmative action in medical school literally saved lives

Leading voice in opioid treatment defends methadone clinic system

hotspot

Baby aspirin cuts fat buildup in liver disease patients, in small study

Why you get paid to donate plasma but not blood

Health AI adoption puts security, privacy startups on investors' radar

Creating egg and sperm cells from stem cells raises ethical issues

Stop the failed accountable care organization experiment

UK homeowners get some respite as inflation falls by more than anticipated to a 15

hotspot

hotspot

focus

knowledge